Cannabis Stocks: If the Rally Isn’t Over, This 1 Looks Attractive

Here’s why Tilray (TSX:TLRY)(NASDAQ:TLRY) remains one of the top cannabis stocks long-term growth investors may want to watch right now.

| More on:
Cannabis stocks have fallen.

Once one of the most-discussed sectors among growth investors, interest in cannabis stocks has waned substantially of late. Indeed, the question of whether retail investors will once again jump on perhaps the “greenest” sector of them all remains to be seen.

Among the cannabis stocks that has been losing momentum of late is Tilray (TSX:TLRY)(NASDAQ:TLRY), fresh of its merger with Aphria. Indeed, as the world’s largest cannabis company (for now), investors will be keeping a close eye on how this company performs moving forward.

Here’s one of the key reasons why Tilray may be one of the Canadian cannabis stocks worth watching right now.

Big U.S. investment puts cannabis stocks back on watch

In addition to Tilray’s massive Aphria merger, there’s another deal that’s grabbing headlines of late. The company recently made a big move to potentially acquire its way into the U.S. market.

Indeed, the potential for Federal legalization in the U.S. looms over cannabis stocks. Should cannabis become legal for recreational use, it’s expected that a rising tide could lift all boats. Accordingly, it appears Tilray is doing its best to be in the water when the tide rises.

By acquiring more than US$165 million of debt in MedMen Enterprises, experts believe Tilray may be making an acquisition run at MedMen. After all, this is a massive investment. It’s understandable that this kind of investment in another company’s debt would preclude an equity investment.

Additionally, this debt is convertible to equity. This means that should Tilray exercise its right to convert this debt to shares, the mega-cap cannabis player could own more than 20% of the voting shares of MedMen.

On top of this, Tilray’s CEO has publicly stated that acquiring MedMen isn’t out of the question. Thus, investors banking on further consolidation certainly have reason to believe there’s more than just smoke with this transaction.

Tilray’s gateway to the U.S. cannabis market

MedMen’s status as one of the preeminent retail chains of U.S. cannabis stores in California, Illinois, Massachusetts, and Nevada is a big deal. Indeed, the vertical integration that MedMen could provide Tilray appears to be a focal point for Tilray’s CEO in terms of his plans to integrate this company into the U.S. market.

Indeed, Tilray appears to be betting on some sort of legalization legislation to proceed forward soon. By getting ahead of the news, Tilray looks to be positioning itself as a key potential player in the U.S. cannabis supply chain. While other cannabis stocks appear to be focused more on their domestic markets, Tilray is aggressively looking at expanding.

For long-term growth investors, perhaps such as strategy will pay off. Indeed, only time will tell. However, for now, Tilray certainly looks enticing. That is, for those who think cannabis stocks still have a long growth runway from here.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any stocks mentioned in this article.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »